| |
|
volgende >> |
|
uienkruid @ 01-07-2010 18:16:04 (http://www.ErikErik.com / CTIC) |
|
beetje proberen op 40 cent wie weet |
|
uienkruid @ 01-07-2010 15:04:07 (http://www.ErikErik.com / CTIC) |
Cell Therapeutics to Retire All Remaining 2010 Convertible Debt
SEATTLE, July 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has deposited $39.3 million in cash as trust funds with U.S. Bank National Association, as the trustee of the outstanding 4% convertible senior subordinated notes (the "Notes"), which is an amount sufficient to pay and discharge the entire amount due on the Notes, including accrued and unpaid interest.
"We are pleased that with recent successful financings we were in a position to retire all of our Notes with a maturity in 2010," said James A. Bianco, M.D., CEO of CTI. "This should eliminate shareholder concerns over our ability to repay the Notes with a maturity in 2010, and we will continue our focus on moving our products forward through the clinic and the regulatory approval process as expeditiously as possible." |
|
edwardo @ 11-06-2010 20:08:00 (http://www.ErikErik.com / CTIC) |
|
Ik zal ze nog lang hebben Ronnie,die 25% maakt nog niet veel goed. |
|
ronnierolex @ 11-06-2010 19:25:36 (http://www.ErikErik.com / CTIC) |
|
jij hebt ze natuurlijk nog ed? |
|
edwardo @ 11-06-2010 18:55:41 (http://www.ErikErik.com / CTIC) |
Cell Therapeutics, Inc. Reports New Data Demonstrating That Complete Responses To Pixuvri Are Correlated With Prolonged Survival In Patients With Relapsed Or Refractory Aggressive NHL
1:30am EDT
Cell Therapeutics, Inc. reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri (pixantrone dimaleate), the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). These analyses demonstrated that patients who achieved a complete response (CR)/unconfirmed complete response (CRu) to Pixuvri had up to a 63% probability of being alive at 24 months compared to a 20% probability for patients treated with comparator agents. The study showed a 21% improvement in overall survival for all patients who received Pixuvri that was independent of factors known to influence survival like prior rituximab use, international prognostic index (IPI) score, prior stem cell transplant, baseline level of LDH (lactate dehydrogenase), or refractory status based on univariate Cox regression analyses of survival. |
|
Bandit @ 24-05-2010 16:16:41 (http://www.ErikErik.com / CTIC) |
klinkt niet best edwardo
Cell Therapeutics (CTIC) often talks about the promise of its pipeline, though it has very little cash to do anything about it. The money raise it did today allows the company to postpone a July 1 bankruptcy to the end of the year. The company doesn't have enough money to complete a new pixantrone pivotal trial required by the FDA for approval. Unless its shareholders vote management 400 million more common shares to play with, Cell Therapeutics can't even raise the money.
Cell Therapeutics is notable because it has spent more than $1.4 billion in shareholder money without ever taking a drug through the approval process. It bought an approved drug and failed miserably at trying to market it. Nevertheless, Cell Therapeutics management manages to keep shareholders from revolting by promising that bigger and better things are just around the corner. One of those “better things” was supposed to be brostallicin, a new cancer drug the company is developing.
However, an abstract of next month's American Society of Clinical Oncology (ASCO) meeting reports that brostallicin badly failed an important randomized Phase II trial.
This was a randomized Phase II trial comparing brostallicin to the chemotherapy drug doxorubicin. They theory behind brostallicin was that it was less toxic and either equally or more effective than older drugs.
In this trial, investigators tried this theory out on patients with metastatic soft-tissue sarcoma (cancer). Patients in this trial were over 60 years of age and not fit enough to receive traditional combination chemotherapy. Patients received either brostallicin or doxorubicin. The primary endpoint of the study was tumor stabilization at 26 weeks. To be considered a success, about half the patients in the brostallicin arm needed to have stable disease or better. A total of 118 patients were enrolled.
Brostallicin failed the primary endpoint. Only 5 of 77 (6.5%) patients had stable disease or better where 37 were needed to call the trial a "success." On the other side, 10 of 36 (27.8%) of the doxorubicin patients had a successful outcome.
The secondary endpoints were no better.
On progression-free survival at one year, brostallicin mustered just 6.5% versus doxorubicin at 15.6%. Overall tumor response rate, the combination of complete and partial responses, had doxorubicin at 21.1% compared to only 3.9% for brostallicin.
One doesn't often see such a drug fail a trial as badly as brostallicin failed this trial. Cell Therapeutics touted the start of a brostallicin trial in triple-negative breast cancer in a press release in late April. Given these results, the smart money wouldn't bet on a successful outcome of this new trial. |
|
edwardo @ 24-05-2010 14:14:52 (http://www.ErikErik.com / CTIC) |
Heb nog een ordertje ingezet op 0.20$
Average down noemen ze dat dan  ,tot wanneer ze nog eens een stuiptrekking krijgen naar boven,want dan vliegen ze eruit.
'k Weet niet goed wat ik er moet van denken... |
|
plumo @ 24-05-2010 11:34:30 (http://www.ErikErik.com / CTIC) |
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $21.0 Million of Preferred Stock and Warrants
http://finance.yahoo.com/news/Cell-Therapeutics-Inc-prnews-250984052.html?x=0&.v=1 |
|
kenijn @ 15-04-2010 17:17:40 (http://www.ErikErik.com / CTIC) |
wacht nog wel even af om te zien wat Novartis doet.
Overname CTIC is heel goed mogelijk, nu CTIC geen geld heeft. Verexdre aandelenuitgifte is niet interessant op $0.64 |
|
Bandit @ 09-04-2010 15:33:18 (http://www.ErikErik.com / CTIC) |
resterende deel aan 0,66 verkocht. Geheel uit ctic, wel mooi winstje mee gemaakt, had meer kunnen zijn.
Nu kan de weg omhoog ingezet worden |
|
henk @ 09-04-2010 10:11:02 (http://www.ErikErik.com / CTIC) |
kenijn @ 23-03-2010 15:56:15 (http://www.ErikErik.com / CTIC)
CTIC wordt overgenomen. Er is eigenlijk geen andere optie.
Voor 5$ mogen ze hem hebben. Dan hebben ze Opaxio, maar ook pix als bonus gratis bijna.
ja en CRL krijgen ze erook gratis bij voor die 5 dollar van je
|
|
edwardo @ 09-04-2010 09:29:08 (http://www.ErikErik.com / CTIC) |
|
SEATTLE, April 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration (the "FDA") regarding its New Drug Application ("NDA") for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory Committee ("ODAC") meeting on March 22, 2010 and recommended the Company conduct an additional trial to demonstrate the safety and effectiveness of its product. Based on the FDA's ODAC presentation, which provided the Committee and the Company with alternative options to consider to make investigational drugs available to patients if drugs need to be studied further prior to approval, the Company has decided to pursue expanded access program for pixantrone while it conducts an additional study in aggressive NHL. |
|
ronnierolex @ 31-03-2010 18:23:19 (http://www.ErikErik.com / CTIC) |
|
die dingen worden gesteld op 0,0001 : waar zit de spread? |
|
advajo @ 31-03-2010 17:25:22 (http://www.ErikErik.com / CTIC) |
 toch de afgelopen weken wel wat "minutentrades" kunnen doen. zat een leuke spread in, maar die is nu nagenoeg verdwenen. |
|
robbie3 @ 31-03-2010 17:03:23 (http://www.ErikErik.com / CTIC) |
|
Lijkt me een heerlijk aandeel om naar te kijken. En af te blijven. |
|
advajo @ 31-03-2010 16:53:22 (http://www.ErikErik.com / CTIC) |
|
voorlopig nog in een downtrend robbie |
|
robbie3 @ 31-03-2010 14:04:56 (http://www.ErikErik.com / CTIC) |
|
Cell Therapeutics To Sell $20 Million of Preferred Stock and Warrants |
|
kenijn @ 30-03-2010 18:34:04 (http://www.ErikErik.com / CTIC) |
|
in 35% van de gevallen keurde FDA een product goed dat eerder door het panel was verworpen. Er is dus 35% kans. |
|
kenijn @ 30-03-2010 18:32:57 (http://www.ErikErik.com / CTIC) |
|
FDA heeft het laatste woord en die kan pix alsnog goedkeuren.FDA gaat niet altijd akkoord met dat zogenaamde panel. |
|
ronnierolex @ 24-03-2010 21:01:33 (http://www.ErikErik.com / CTIC) |
|
maandag 0,12? meen je niet ; die hek ff gemist |
|
Edwardo @ 24-03-2010 17:52:31 (http://www.ErikErik.com / CTIC) |
Hier klopt toch iets niet hoor,ik blijf ze vast houden.
Maandag een dump tot 0.12$ en nu alweer op 0.73$.
Wie is hier alles aan het kopen? |
|
henk @ 23-03-2010 16:17:06 (http://www.ErikErik.com / CTIC) |
|
chapter 11 bestaat ook hoor |
|
kenijn @ 23-03-2010 15:56:15 (http://www.ErikErik.com / CTIC) |
CTIC wordt overgenomen. Er is eigenlijk geen andere optie.
Voor 5$ mogen ze hem hebben. Dan hebben ze Opaxio, maar ook pix als bonus gratis bijna. |
|
graaier @ 23-03-2010 14:37:28 (http://www.ErikErik.com / CTIC) |
 |
|
graaier @ 23-03-2010 14:37:02 (http://www.ErikErik.com / CTIC) |
|
|
| |
